Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Long-term Extension in Pediatric MDD
NCT03108625Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Treatment-Emergent Adverse Events at Week 104. Started Mar 2017; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03108625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108625.